DDInter1119 DDInter1940
Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
Vismodegib is an orally active small molecule that inhibits the hedgehog signaling pathway by binding to and inhibiting the transmembrane protein smoothened homologue (SMO).[A258613,A258618,L45803] It was discovered by high-throughput screening of a library of small-molecule compounds and subsequent optimization through medicinal chemistry. Since it targets the hedgehog signaling pathway, vismodegib has anti-tumor activity in basal-cell carcinoma. The Hedgehog signaling pathway plays an important role in the development of organs and tissues during embryogenesis. Afterwards, it is silenced in all cells and tissues, except for hair, skin and stem cells. However, dysregulated or aberrant Hedgehog signaling has been associated with basal cell carcinoma pathogenesis.[A258608,L45803] In January 2012, vismodegib was approved by the FDA for the treatment of adult basal cell carcinoma. In July 2013, it was approved by the EMA, and since then, it has been approved by several other countries.[A7370,A258618,L45803]
Magnesium oxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetohexamide
Acetohexamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sulfasalazine
Sulfasalazine {u} (Compound) resembles {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Digoxin
Digoxin {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Vismodegib
Magnesium oxide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eltrombopag
Eltrombopag {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Vismodegib
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Vismodegib (Compound)
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib and Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Sulfasalazine and Sulfasalazine (Compound) resembles Vismodegib (Compound)
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Vismodegib (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Vismodegib (Compound)
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Vismodegib (Compound)
Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Vismodegib (Compound)
Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Vismodegib (Compound)